Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blinded placebo-controlled trial

What Was Tested

Researchers studied Octreotide in the context of delayed gastric emptying on glp-1 medicines and pancreatitis (after the acute phase) in this randomized controlled trial publication.

To evaluate the impact of prophylactic octreotide on gastric emptying in patients undergoing pancreaticoduodenectomy.

Postoperative pancreatic fistula (POPF) and delayed gastric emptying (DGE) are common complications after pancreaticoduodenectomy.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Patients were randomized to the placebo group (n=32) and the octreotide group (n=35).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Octreotide group and the comparison group should start out alike.

As a double-blind Octreotide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Octreotide could be set against what happens without it.

In this prospective, randomized, double-blinded, placebo-controlled trial the researchers analyzed the influence of prophylactic octreotide on delayed gastric empting after pancreaticoduodenectomy.

Primary endpoint was the incidence of delayed gastric emptying, secondary endpoints included perioperative morbidity other than DGE.

DGE was measured by clinical signs, gastric scintigraphy and the hydrogen breath test.

Risk factors for DGE other than octreotide were analyzed by univariate and multivariate analyses.

What Was Measured

The subject headings attached to it are Gastric Emptying, Gastrointestinal Agents, Octreotide, Pancreatic Fistula, Pancreaticoduodenectomy and Risk Factors.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide in people with delayed gastric emptying on glp-1 medicines.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology), a journal based in England.

More context: the Octreotide compound page, Delayed gastric emptying on GLP-1 medicines research, Pancreatitis (after the acute phase) research.